Discover the next revolutionary biomarkers with us
— HIGH QUALITY IHC SERVICES FIT FOR ANY STAGE OF RESEARCH AND DEVELOPMENT —
Preclinical and Translational Studies
We apply expert knowledge of fundamental biological processes to understand targets in preclinical models and accelerate the transition to the next stage of development
We take a "leave no stone unearthed" approach in assay development and develop high-quality assays with proper controls using testing methods and materials intended for large clinical trials.
Over 25 years of experience in assay development and validation supporting over 1,000 clinical trials, both prospective and retrospective.
Proven proprietary workflows and expertise in developing robust scoring schemes to properly and consistently capture level of target expression.
Get high quality results at speed and scale to accelerate global clinical trials using a single chain of custody that adheres to all appropriate regulations and quality standards
Diagnostics Prototype Development
Discovery developed the prototype companion diagnostic IHC test for Pembrolizumab which is the first drug approved for lung cancer patients whose tumors express PD-L1.
Discovery Biomarker Academy™
Accelerate post-market adoption with expert training and concordance studies for pathologists and technicians.
Work with a reliable biomarker expert today to accelerate your success.
"We worked with 3 histology vendors to develop IHC assay for novel tumor antigen using commercially available IHC antibodies. Only the DLS team was able to deliver robust and specific assay with staining characteristics that were suitable for our range-finding studies. Leveraging their in-house biorepository, DLS was able to deliver a data package with scoring intensities for this antigen for 178 patient samples across 13 cancer indications. This information has been extremely valuable in understanding the clinical opportunity that targeting this antigen would provide."
- Eric Tam, PhD, Sr. Director of Research at EvolveImmune Therapeutics
“We have been working with Discovery Life Sciences in Kassel, previously Targos GmbH, for many years on clinical validation of tissue biomarkers. This partnership is based on strong scientific focus and an open and honest relationship which led to the approvals of many companion diagnostics assays for Agilent and our pharma partners. We always appreciate the consistent high-quality services and the mutual trust we've developed over the years across our various internal functions such as R&D, Marketing, CDx, and Clinical Trials. DLS has also established a fantastic Biomarker Academy training program that, in my opinion, has become a valuable cornerstone in the global pathology community.”
- Majken Nielsen, Associate Vice President, Head of Global Marketing, Pathology Division at Agilent Technologies
“In the past five of years, we have entrusted Discovery Life Sciences with the development and validation of a FISH assay for a novel biomarker (MAF-Test) predicting relapse in breast cancer and the response to specific drugs in adjuvant setting. DLS's expertise in assay development and target validation helps create a reliable scoring scheme accelerating identification of patients eligible for further treatment. Furthermore, DLS's experience in molecular pathology and consultative service approach always exceeded our expectations”
- Joël Jean-Mairet PhD, Executive Chairman, Inbiomotion SL
Expertise across different molecular pathology platforms in CLIA-certified, CAP-accredited, and GCLP-compliant laboratories.
To propel your projects with The Power of Discovery.™
Contact Us Today
Let us know about your project!